CN108676065A - 一种抗Aβ蛋白聚集的四肽及其应用与编码该四肽的基因 - Google Patents
一种抗Aβ蛋白聚集的四肽及其应用与编码该四肽的基因 Download PDFInfo
- Publication number
- CN108676065A CN108676065A CN201810504178.8A CN201810504178A CN108676065A CN 108676065 A CN108676065 A CN 108676065A CN 201810504178 A CN201810504178 A CN 201810504178A CN 108676065 A CN108676065 A CN 108676065A
- Authority
- CN
- China
- Prior art keywords
- albumen
- tetrapeptide
- aggregation
- amino acid
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 18
- 230000004845 protein aggregation Effects 0.000 title description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 26
- 230000006933 amyloid-beta aggregation Effects 0.000 claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 150000001413 amino acids Chemical group 0.000 claims description 33
- 235000001014 amino acid Nutrition 0.000 claims description 24
- 229940024606 amino acid Drugs 0.000 claims description 24
- 108020004705 Codon Proteins 0.000 claims description 9
- 230000002776 aggregation Effects 0.000 claims description 7
- 238000004220 aggregation Methods 0.000 claims description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 229940100688 oral solution Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 61
- 229920001184 polypeptide Polymers 0.000 abstract description 55
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 55
- 230000015572 biosynthetic process Effects 0.000 abstract description 27
- 238000003786 synthesis reaction Methods 0.000 abstract description 27
- 238000000034 method Methods 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 6
- 208000012902 Nervous system disease Diseases 0.000 abstract description 5
- 208000025966 Neurological disease Diseases 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 230000001934 delay Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 28
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- 239000002585 base Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 239000003875 Wang resin Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000003746 solid phase reaction Methods 0.000 description 3
- 238000010671 solid-state reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 1
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 1
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QFJAZXGJBIMYLJ-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;ethane-1,2-diamine Chemical compound NCCN.OC(=O)C(O)C(O)C(O)=O QFJAZXGJBIMYLJ-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- JRBVWZLHBGYZNY-QEJZJMRPSA-N Asp-Gln-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JRBVWZLHBGYZNY-QEJZJMRPSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- WBOHXLDSPBIPTP-UHFFFAOYSA-N N,N-dimethyl-1,8-naphthyridin-4-amine Chemical compound CN(C1=CC=NC2=NC=CC=C12)C WBOHXLDSPBIPTP-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102220470576 Protein ripply1_E22G_mutation Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000004914 glial activation Effects 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- MPNNOLHYOHFJKL-UHFFFAOYSA-N peroxyphosphoric acid Chemical compound OOP(O)(O)=O MPNNOLHYOHFJKL-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004697 synapse damage Effects 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了一种抗Aβ42蛋白聚集的四肽及其应用与编码该四肽的基因。本发明的合成多肽具有显著抗Aβ42蛋白聚集的功效,进而具有改善记忆、延缓阿尔兹海默症发病进程的作用,可广泛应用于制备抗Aβ42蛋白聚集的药物或食品,或者应用于制备预防或治疗阿尔兹海默症的药物或食品,进而能对包括AD疾病的神经退行疾病进行有效预防和治疗,改善神经退行疾病医疗状况,具有重大社会和经济效益。
Description
技术领域
本发明涉及多肽技术领域,特别涉及一种合成多肽及其应用以及编码该四肽的基因。
背景技术
阿尔兹海默病(AD)又称老年痴呆症,是一种起病隐匿的进行性中枢神经系统退行性疾病。AD临床表现为病人在意识清醒的状态下智能全面减退,包括记忆力、注意力、计算力、判断力、抽象思维能力、语言功能等减退,同时出现情感和行为障碍。患病后期,AD患者记忆力严重丧失,日常生活不能自理,大小便失禁,呈现缄默、肢体僵直症状,查体可见椎体束征阳性,有强握、摸索和吮吸等原始反射,最终昏迷,因感染等原因致死。流行病学调查结果显示,AD发病率与年龄正相关,为老年人群高发疾病。截止于2015年,全世界65岁以上人口AD患者达5000万以上,预计2020年将增加50%。每年死于AD的老年人占总数的1/3以上,年均死亡率超过500,000例。AD与其他三类老年主要疾病心血管疾病、肿瘤、脑卒中相匹敌,已成为老年人的第四大杀手。目前,AD的主要发病原因尚不清楚,流行病学研究多认为患者在环境、遗传、社会等多种因素作用下发病,包括头部外伤、教育水平低、病毒感染、遗传、甲状腺疾病等。AD发病机制尚未明确,科学研究提出多种假说但均在实验验证阶段,给AD的治疗和药物研发造成极大困难。早期诊断主要方法脑脊液检测为有损分析,又极大阻碍了AD常规性检测的普及。因此,一个世纪以来,随着社会老龄化的日趋严重,AD发病率的逐渐上升,AD的早期预防、病情诊断以及治疗预后成始终是医疗界的重大挑战。
已有的研究对AD发病机制提出多种假说,包括Aβ级联假说、微管相关蛋白-tau蛋白异常假说、中枢胆碱能损伤假说、基因突变或多型性学说、免疫功能突变假说、兴奋性氨基酸毒性学说等等。其中,Aβ级联假说是最有影响力的主流假说之一。Aβ级联假说提出,淀粉样蛋白Aβ积累形成寡聚体,进而引起微妙的突触损伤、胶质细胞活化、炎症、氧化应激和Tau蛋白过磷酸化等病理变化,导致广泛的突触功能异常,选择性的神经元死亡,认知功能障碍。Aβ淀粉蛋白寡聚体毒性在细胞、动物模型均得以验证。因此,基于Aβ级联假说的病理细胞模型、动物模型在AD机制研究和药物活性筛选得到广泛应用。研究证明Aβ42是多种淀粉样蛋白中最具神经毒性的一种。Aβ42寡聚体与神经元和非神经元细胞膜上的多种成分,包括脂类、受体、离子通道等相结合引起一系列复杂的突触、神经元和神经元网络功能结构异常,导致学习、记忆等行为异常。本发明使用E22G-Aβ42-mCherry HEK-293转基因细胞模型,通过胞内表达Aβ42-mCherry蛋白,良好的模拟了Aβ42在细胞内聚集、产生毒性的过程,模拟AD患者体内神经元细胞老年斑的病理发展过程,通过插入AD患者基因突变亚型E22G增强Aβ42的聚集性,并通过对Aβ42蛋白标记mCherry红色荧光蛋白追踪其的集聚,最终借助显微镜观察、拍摄等手段实现可视化快速AD药物筛选。
治疗AD的药物,常见药物包括胆碱能药物、改善脑循环或脑代谢的药物、神经保护药物、抗氧化剂、中药等。乙酰胆碱酯酶抑制剂能够抑制乙酰胆碱酯酶的活性,减少脑内乙酰胆碱的分解,从而缓解AD症状,是现阶段最有效的治疗药物。免疫疗法(包括主动免疫和被动免疫)作为一种新的治疗手段,可减少AD的病理损害,延缓或逆转认知能力下降。但AD的治疗,始终缺乏特异性强、缓解且逆转病情,提高疾病治疗预后的有效药物。多肽类药物的出现为寻找高选择性、高效、低毒的AD治疗方法和药物研发提供了新方向。脑蛋白水解物为一种神经营养性多肽混合物,富含游离氨基酸、低分子多肽及镁、钾、磷、硒等多种元素,治疗阿尔兹海默症有一定疗效,多项研究显示脑蛋白水解物能显著改善患者的记忆、疲劳、眩晕、焦虑等症状。脑苷肌肽目前在临床上使用取得了较好的疗效。脑啡肽作为一种五肽,除抑制神经传递,起镇痛作用,同时因神经元保护作用成为了AD的潜力治疗药物。
已有的AD多肽类药物为多肽类药物的筛选奠定了基础,揭示了多肽作为AD药物的重大潜力。
发明内容
本发明的目的在于针对现有技术的不足,提供了一种抗Aβ42蛋白聚集的四肽。
本发明的目的还在于提供编码所述的一种抗Aβ42蛋白聚集的四肽的基因。
本发明的另一目的还在于提供所述的一种抗Aβ42蛋白聚集的四肽的应用。
本发明的目的通过如下技术方案实现。
一种抗Aβ42蛋白聚集的合成多肽,名称为WW-4,氨基酸序列为:Trp-Asp-Gln-Trp,如序列表SEQ ID No:1所示;
其中,Trp为色氨酸的氨基酸相应残基,Asn为天冬酰胺的氨基酸相应残基,Gln为谷氨酸的氨基酸相应残基。
一种编码所述的抗Aβ42蛋白聚集的合成多肽的基因,碱基序列为UGGGAUCAAUGG碱基编码而成,如序列表SEQ ID No:2所示,基因长度为12个碱基;
其中,UGG为色氨酸的密码子,GAU为天冬氨酸的密码子,CAA为谷氨酸的密码子。
合成所述的一种抗Aβ42蛋白聚集的合成多肽即四肽的方法,采用多肽固相合成法合成或基因工程技术合成。
所述的一种抗Aβ42蛋白聚集的合成多肽的应用,包括应用于制备抗Aβ42蛋白聚集的药物或食品,或者应用于制备预防或治疗阿尔兹海默症的药物或食品。
优选的,所述药物的剂型包括膏剂、颗粒剂、丸剂、散剂、片剂、胶囊剂、口服液或糖浆剂。
优选的,所述食品为保健食品,剂型包括颗粒剂、胶囊剂、糖浆剂、片剂、粉剂、软糖、乳剂或口服液。
与现有技术相比,本发明具有如下优点和有益效果:
本发明的合成多肽Trp-Asp-Gln-Trp具有显著抗Aβ42蛋白聚集的功效,进而具有改善记忆、延缓阿尔兹海默症发病进程的作用,可广泛应用于制备抗Aβ42蛋白聚集的药物或食品,或者应用于制备预防或治疗阿尔兹海默症的药物或食品,进而能对包括AD疾病的神经退行疾病进行有效预防和治疗,改善神经退行疾病医疗状况,具有重大社会和经济效益。
附图说明
图1a为实施例1合成的多肽WW-4的高效液相色谱图;
图1b为实施例1合成的多肽WW-4的液相色谱-质谱/质谱(LC-MS)图;
图2a为实施例2中阴性对照组(Control group)的IncuCyte Zoom长时间活细胞成像图;
图2b为实施例2中模型组(Model group)的IncuCyte Zoom长时间活细胞成像图;
图3a为实施例2中合成多肽WW-4浓度为0.05mM的多肽低剂量组的IncuCyte Zoom长时间活细胞成像图;
图3b为实施例2中合成多肽WW-4浓度为0.5mM的多肽高剂量组的IncuCyte Zoom长时间活细胞成像图;
图4为实施例2中阴性对照组、模型组、0.05mM的多肽低剂量组和0.5mM的多肽高剂量组的Aβ42蛋白聚集率柱形图。
具体实施方式
以下结合具体实施例及附图对本发明的技术方案作进一步详细的描述,但本发明的保护范围及实施方式不限于此。
具体实施例中,本发明的一种抗Aβ42蛋白聚集的合成多肽,名称为WW-4,氨基酸序列如氨基酸序列表SEQ ID NO:1所示,氨基酸序列为:Trp-Asp-Gln-Trp;
其中,Trp为色氨酸的氨基酸相应残基,Asn为天冬酰胺的氨基酸相应残基,Gln为谷氨酸的氨基酸相应残基;
分子结构式如下所示:
编码上述的抗Aβ42蛋白聚集的合成多肽的基因,碱基序列为UGGGAUCAAUGG碱基编码而成,如序列表SEQ ID No:2所示,基因长度为12个碱基;
其中,UGG为色氨酸的密码子,GAU为天冬氨酸的密码子,CAA为谷氨酸的密码子。
本发明的抗Aβ42蛋白聚集的合成多肽可通过多肽固相合成法或基因工程技术合成;具体操作步骤如下:
树脂选用2-chlorotrityl chloride resin树脂或Wang树脂;采用Fmoc保护氨基酸N端,各保护氨基酸为Fmoc-Trp(boc)-OH、Fmoc-Asp(tbu)-OH和Fmoc-Gln(trt)-OH。保护氨基酸和树脂进行逐一偶联可采用固相合成领域常规的偶联试剂和活化试剂,包括采用4-二甲氨基吡啶(DMAP)和二环己基碳二亚胺(DCC)完成第一个保护氨基酸和树脂的偶联,采用1-羟基苯并三唑(HOBt)进行余下保护氨基酸之间的偶联。按照多肽C端到N端的氨基酸顺序,将保护氨基酸和树脂进行逐一偶联,然后裂解液脱除树脂和保护氨基酸侧链保护基,获得粗品,粗品纯化后,获得抗Aβ42蛋白聚集的合成多肽。
通过基因工程技术合成时,将编码多肽的基因插入到载体中,再将载体转录到原核表达体系大肠杆菌中或真核表达体系酵母中进行表达,然后对目标多肽进行分离纯化,获得抗Aβ42蛋白聚集的合成多肽。
具体实施例中,本发明基于Aβ级联假说,采用E22G-Aβ42-mCherryHEK-293转基因细胞模型对的获得的合成多肽WW-4进行AD老年斑体外研究。
E22G-Aβ42-mCherry HEK-293转基因细胞模型内能表达Aβ42-mCherry蛋白,良好地模拟了Aβ42在细胞内聚集、产生毒性的过程,模拟AD患者体内神经元细胞老年斑的病理发展过程,并通过对Aβ42蛋白标记mCherry红色荧光蛋白追踪其的集聚,最终借助显微镜观察、拍摄等手段实现可视化快速AD药物筛选。
实施例1
多肽固相合成法合成多肽WW-4
1、树脂选型
(1)采用标准Fomc方案,起始选用0.0125mmol 2-chlorotrityl chlorideresin树脂(天津市南开合成科技有限公司),按照氨基酸序列Trp-Asp-Gln-Trp的C端到N端的序列特征,加入0.3mol第一个Fmoc保护氨基酸,将DCC和5%(质量分数)DMAP加入到反应器振荡反应,用甲基吡咯烷酮(NMP)冲洗树脂除去多余保护氨基酸。
(2)采用标准Fomc方案,起始选用0.0125mmol Wang树脂,按照氨基酸序列Trp-Asp-Gln-Trp的C端到N端的序列特征,加入0.3mol第一个Fmoc保护氨基酸,将DCC和5%(质量分数)DMAP加入到反应器振荡反应,用NMP冲洗树脂除去多余保护氨基酸。
两种树脂耦合率分别为:2-chlorotrityl chloride resin树脂为95.07%,Wang树脂为98.01%。
2、合成过程
采用标准Fomc方案,选用偶合率较高的Wang树脂,按照氨基酸序列Trp-Asp-Gln-Trp的序列特征,使肽链从C端逐个向N端延伸,各氨基酸的用量为0.1mol,加入0.5mol Fmoc保护氨基酸,每步缩合都加入HOBt活化保护氨基酸的羧基,每步缩合采用20%哌啶/DMF溶液(15mL/g)处理20min,去除Fmoc保护基;肽侧链合成后,将含有树脂的肽链加入到体积比99:1的二氯甲烷:三氟乙酸的混合液中,将肽链从树脂上切割下来;再次将多肽加入到体积比94.5:2.5:2:1的三氟乙酸:酒石酸乙二胺:蒸馏水:胰蛋白酶抑制剂(TIS)的混合液中反应2h,脱去侧链保护基。
以上过程均在SYMPHONY型12通道多肽合成仪中完成,合成的多肽经SHIMADZU高效液相色谱仪纯化,纯度达到99%以上,并采用液相色谱-质谱/质谱(LC-MS)进行定性分析,测定其氨基酸序列。
合成的多肽的高效液相色谱图和液相色谱-质谱/质谱(LC-MS)图分别如图1a和图1b所示,由图1a和图1b分析表明,合成的多肽的一级氨基酸序列是Trp-Asp-Gln-Trp,即得到目标多肽,合成获得抗Aβ42蛋白聚集的合成多肽。
实施例2
合成多肽WW-4体外抗Aβ42蛋白聚集的活性实验
1、实验方法
培养基的配制:高糖培养基(DMEM)、胎牛血清(FBS)、L-谷氨酰胺分别按照质量比8.75:1:0.25配制;同时加入1wt%的双抗(青霉素和链霉素)、0.1wt%的Hygromycin B和0.05wt%的Blasticidin S抗生素。
0.05mM和0.5mM的多肽(WW-4)溶液配制:称取11.4mg的多肽WW-4,用10mL的培养基溶解,过0.22μm的滤头后,母液浓度为1mM,再用培养基将母液稀释至实验所需浓度。
1mg/mL四环素溶液配制:称取10mg的四环素,用10mL的PBS缓冲液配制,过0.22μm的滤头后,-20℃避光保存备用。
细胞实验采用E22G-Aβ42-mCherry HEK-293细胞和E22G-Aβ42-mCherry HEK-293细胞进行培养和实验。实验分组:阴性对照组(Control group,mCherry HEK-293细胞,不表达Aβ42蛋白);模型组(Model group,E22G-Aβ42-mCherry HEK-293细胞,表达Aβ42蛋白);多肽WW-4低剂量组(0.05mM的多肽WW-4溶液,E22G-Aβ42-mCherry HEK-293细胞,表达Aβ42蛋白)和多肽WW-4高剂量组(0.5mM的多肽WW-4溶液,E22G-Aβ42-mCherry HEK-293细胞,表达Aβ42蛋白),每组设三个平行。
用24孔板进行细胞铺板,每孔的细胞个数是4000,贴壁24h后,按照实验分组分别加入培养基和多肽溶液。培养48h后,加入四环素(终浓度为20μg/mL)进行诱导,采用IncuCyte Zoom长时间活细胞成像仪进行实时跟踪拍照,观察四环素加入后,细胞中蛋白聚集情况变化,该过程持续72h后结束。仪器进行白光和荧光的双重拍照,拍照放大倍数为200倍,每间隔4h进行一次拍照,每孔拍9个视野,观察红色荧光聚集点个数,计算蛋白聚集率。
Aβ42蛋白聚集率=视野中红色荧光点个数/细胞面积百分比。
2、实验结果
阴性对照组(Control group)是不表达目的蛋白Aβ42表达的细胞,模型组(Modelgroup)则是表达目的蛋白Aβ42的细胞,阴性对照组(Control group)和模型组(Modelgroup)的IncuCyte Zoom长时间活细胞成像图分别如图2a和图2b所示,多肽WW-4浓度为0.05mM的多肽低剂量组和0.5mM的多肽高剂量组的IncuCyte Zoom长时间活细胞成像图分别如图3a和图3b所示,而阴性对照组、模型组、0.05mM的多肽低剂量组和0.5mM的多肽高剂量组的Aβ42蛋白聚集率柱形图如图4所示,图中*代表p<0.05,**代表p<0.01;
由图2a和图2b可知,阴性对照组没有红色荧光聚集点存在,而模型组细胞中Aβ42蛋白表达的红色荧光聚集点较阴性对照组显著增加;由图3a和图3b可知,多肽WW-4的低剂量组(0.05mM)和高剂量组(0.5mM)与模型组相比,低剂量组细胞中的Aβ42蛋白红色荧光聚集点明显减少;而由图4可知,多
肽WW-4的低剂量组(0.05mM)和高剂量组(0.5mM)与模型组相比,蛋白聚集率显著降低,而且高剂量组的效果较模型组变化不显著,出现高浓度抑制,呈一定浓度依赖性。
上述结果表明,多肽WW-4给药剂量为0.05mM时具有显著的抗Aβ42蛋白聚集功效,具有改善记忆、抑制阿尔兹海默症发展的作用,可应用于制备抗Aβ42蛋白聚集的药物或食品,或者应用于制备预防或治疗阿尔兹海默症的药物或食品,进而能对包括AD疾病的神经退行疾病进行有效预防和治疗,改善神经退行疾病医疗状况。
以上实施例仅为本发明较优的实施方式,仅用于解释本发明,而非限制本发明,本领域技术人员在未脱离本发明精神实质与原理下所作的任何改变、替换、组合、简化、修饰等,均应为等效的置换方式,均应包含在本发明的保护范围内。
序列表
<110> 华南理工大学
<120> 一种抗Aβ蛋白聚集的四肽及其应用与编码该四肽的基因
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 4
<212> PRT
<213> 四肽(Tetrapeptide)
<400> 1
Thr Ala Gly Thr
1
<210> 2
<211> 12
<212> DNA/RNA
<213> 四肽(Tetrapeptide)
<400> 2
ugggaucaau gg 12
Claims (5)
1.一种抗Aβ42蛋白聚集的四肽,其特征在于,名称为WW-4,氨基酸序列为:Trp-Asp-Gln-Trp,如序列表SEQ ID No:1所示;
其中,Trp为色氨酸的氨基酸相应残基,Asn为天冬酰胺的氨基酸相应残基,Gln为谷氨酸的氨基酸相应残基。
2.一种编码权利要求1所述的抗Aβ42蛋白聚集的四肽的基因,其特征在于,碱基序列为UGGGAUCAAUGG,如序列表 SEQ ID No:2所示,基因长度为12个碱基;
其中,UGG为色氨酸的密码子,GAU为天冬氨酸的密码子,CAA为谷氨酸的密码子。
3.权利要求1所述的一种抗Aβ42蛋白聚集的四肽的应用,其特征在于,应用于制备抗Aβ42蛋白聚集的药物或食品,或者应用于制备预防或治疗阿尔兹海默症的药物或食品。
4.根据权利要求3所述的应用,其特征在于,所述药物的剂型包括膏剂、颗粒剂、丸剂、散剂、片剂、胶囊剂、口服液或糖浆剂。
5.根据权利要求3所述的应用,其特征在于,所述食品为保健食品,剂型包括颗粒剂、胶囊剂、糖浆剂、片剂、粉剂、软糖、乳剂或口服液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810504178.8A CN108676065A (zh) | 2018-05-24 | 2018-05-24 | 一种抗Aβ蛋白聚集的四肽及其应用与编码该四肽的基因 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810504178.8A CN108676065A (zh) | 2018-05-24 | 2018-05-24 | 一种抗Aβ蛋白聚集的四肽及其应用与编码该四肽的基因 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108676065A true CN108676065A (zh) | 2018-10-19 |
Family
ID=63807924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810504178.8A Pending CN108676065A (zh) | 2018-05-24 | 2018-05-24 | 一种抗Aβ蛋白聚集的四肽及其应用与编码该四肽的基因 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108676065A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109369780A (zh) * | 2018-11-16 | 2019-02-22 | 无限极(中国)有限公司 | 一种四肽及其制备方法与用途 |
CN113150065A (zh) * | 2021-03-11 | 2021-07-23 | 武汉英纳氏药业有限公司 | 一种合成肽及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5814646A (en) * | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
CN101845438A (zh) * | 2009-03-25 | 2010-09-29 | 北京锐健特生物技术有限公司 | 20种肿瘤特异相关的基因与产物的癌症的灵敏诊断与相关治疗 |
CN103910781A (zh) * | 2014-03-18 | 2014-07-09 | 重庆大学 | 一种Aβ聚集抑制剂 |
CN105061561A (zh) * | 2015-07-21 | 2015-11-18 | 天津大学 | 用于抑制β淀粉样蛋白聚集的多肽和多肽功能化的金纳米粒子及制备和应用 |
CN105175493A (zh) * | 2015-09-12 | 2015-12-23 | 复旦大学 | 一种具有抑制Aβ聚集活性的多肽及其用途 |
CN105237628A (zh) * | 2015-11-17 | 2016-01-13 | 南开大学 | 一种用于治疗阿尔兹海默症的多肽 |
-
2018
- 2018-05-24 CN CN201810504178.8A patent/CN108676065A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5814646A (en) * | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
CN101845438A (zh) * | 2009-03-25 | 2010-09-29 | 北京锐健特生物技术有限公司 | 20种肿瘤特异相关的基因与产物的癌症的灵敏诊断与相关治疗 |
CN103910781A (zh) * | 2014-03-18 | 2014-07-09 | 重庆大学 | 一种Aβ聚集抑制剂 |
CN105061561A (zh) * | 2015-07-21 | 2015-11-18 | 天津大学 | 用于抑制β淀粉样蛋白聚集的多肽和多肽功能化的金纳米粒子及制备和应用 |
CN105175493A (zh) * | 2015-09-12 | 2015-12-23 | 复旦大学 | 一种具有抑制Aβ聚集活性的多肽及其用途 |
CN105237628A (zh) * | 2015-11-17 | 2016-01-13 | 南开大学 | 一种用于治疗阿尔兹海默症的多肽 |
Non-Patent Citations (1)
Title |
---|
YANG LIU等: "Identification of two novel peptides with antioxidant activity and their potential in inhibiting amyloid-β aggregation in vitro", 《FOOD & FUNCTION》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109369780A (zh) * | 2018-11-16 | 2019-02-22 | 无限极(中国)有限公司 | 一种四肽及其制备方法与用途 |
CN109369780B (zh) * | 2018-11-16 | 2020-11-06 | 无限极(中国)有限公司 | 一种四肽及其制备方法与用途 |
CN113150065A (zh) * | 2021-03-11 | 2021-07-23 | 武汉英纳氏药业有限公司 | 一种合成肽及其应用 |
CN113150065B (zh) * | 2021-03-11 | 2022-07-08 | 武汉英纳氏药业有限公司 | 一种合成肽及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sanchez-Varo et al. | Transgenic mouse models of Alzheimer’s disease: An integrative analysis | |
Pelin et al. | Palytoxin-containing aquarium soft corals as an emerging sanitary problem | |
Tirta Ismaya et al. | Lectins from the edible mushroom Agaricus bisporus and their therapeutic potentials | |
Prasasty et al. | Natural peptides in drug discovery targeting acetylcholinesterase | |
Chiarini et al. | Danger-sensing/patten recognition receptors and neuroinflammation in Alzheimer’s disease | |
Bonanni et al. | Physical exercise and health: a focus on its protective role in neurodegenerative diseases | |
US20130189382A1 (en) | Use of fucoxanthin in the preparation of product for improving memory and having neuroprotective effect associated with neurodegenerative disorder | |
JPH03503522A (ja) | 溶菌ペプチドによる真核性病原体と新生物の抑制及び線維芽細胞とリンパ球の刺激 | |
Ferreira et al. | Protein dynamics, folding and misfolding: from basic physical chemistry to human conformational diseases | |
Li et al. | Neuroprotective effects of exendin-4 in rat model of spinal cord injury via inhibiting mitochondrial apoptotic pathway | |
Mele et al. | Neuroinflammation and hypothalamo-pituitary dysfunction: focus of traumatic brain injury | |
ES2704859T3 (es) | Péptido para inducir apoptosis específica de mastocitos y su uso | |
Kasindi et al. | Glatiramer acetate immunomodulation: evidence of neuroprotection and cognitive preservation | |
CN108676072A (zh) | 一种具有抗Aβ42蛋白聚集功能的多肽及其应用与编码该多肽的基因 | |
Xu et al. | Effect of marine collagen peptides on physiological and neurobehavioral development of male rats with perinatal asphyxia | |
Wang et al. | Rhodamine B-conjugated encrypted vipericidin nonapeptide is a potent toxin to zebrafish and associated with in vitro cytotoxicity | |
CN108676065A (zh) | 一种抗Aβ蛋白聚集的四肽及其应用与编码该四肽的基因 | |
CN107922461A (zh) | 广谱抗感染肽 | |
Lana et al. | Space-dependent glia–neuron interplay in the hippocampus of transgenic models of β-amyloid deposition | |
Mantuano et al. | Branched-chain amino acids and di-alanine supplementation in aged mice: A translational study on sarcopenia | |
Lin et al. | Discovery of a novel antimicrobial peptide, Temporin-pke, from the skin secretion of Pelophylax kl. esculentus, and evaluation of its structure-activity relationships | |
CN103848914B (zh) | 一种具抗凝活性的菲牛蛭素多肽及其制备方法与用途 | |
CN105440103A (zh) | 从皱纹盘鲍鲍鱼内脏中分离的抗炎肽及其用途 | |
Pawar et al. | Synthesis and anti-leishmanial activity of TRIS-glycine-β-alanine dipeptidic triazole dendron coated with nonameric mannoside glycocluster | |
CN104628822B (zh) | 一种晚期糖基化终产物受体的特异性拮抗肽及其衍生物与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181019 |